a separate trial of LCZ696 in patients with heart failure and a preserved ejection fraction, there was no relationship between the blood-pressure effect and the natriuretic peptide level. 8 PARADIGM-HF may well represent a new threshold of hope for patients with heart failure. Efforts to design novel pharmacotherapies that exploit our growing knowledge of pathophysiological pathways are increasingly coming to the clinical arena. The dual (or more) action of such drugs may translate into even greater long-term survival for patients (Fig. 1) . 9, 10 The beneficial results seen in PARADIGM-HF may apply to a wide spectrum of patients, even those who are currently receiving the best possible therapy.
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A Call to Action for Acute Lymphoblastic Leukemia
Timothy A. Graubert, M.D.
The cure rates for precursor B-cell acute lymphoblastic leukemia (ALL) among children have improved, but the prognosis for older patients and children with relapsed disease remains poor. Risk stratification based on clinical features and disease characteristics can improve outcomes by enabling physicians to reduce the toxicity of therapy for patients with lower-risk disease and intensify therapy for patients with higher-risk disease. The negative prognosis associated with the t(9;22) translocation, which results in expression of the BCR-ABL1 activated kinase fusion protein, is attenuated by treatment that includes tyrosine kinase inhibitors, providing a paradigm for molecularly guided therapy in patients with precursor B-cell ALL. Several years ago, a subtype of precursor B-cell ALL was identified that shares a gene-expression profile with Ph-positive ALL (the term commonly used to describe ALL associated with the Philadelphia chromosome, which results from the t[9;22] translocation). 1,2 The pattern of gene expression in patients with Ph-like ALL prompted the hypothesis that other oncogenic drivers could substitute for BCR-ABL1, triggering a similar signaling cascade. Indeed, previous studies have identified rearrangements and mutations that activate cytokine receptor signaling in some cases of Ph-like ALL. 3, 4 In this issue of the Journal, Roberts et al. 5 define the frequency and genomic landscape of Ph-like ALL in a cohort of 1725 children and young adults with precursor B-cell ALL. They observed a marked rise in the proportion of Ph-like cases with age, from 12% among children to 27% among young adults (Fig. 1A) . Nearly half (49.4%) of the young adults had either Ph-positive or Ph-like disease. The Ph-like cases were frequently found to be associated with IKZF1 alterations (in 68% of patients with Ph-like ALL) and high CRLF2 expression (in 47%), with the latter caused by genomic rearrangement in all ABL2, or CSF1R were sensitive to ABL inhibitors (imatinib or dasatinib), and JAK2 fusions were sensitive to a Janus kinase inhibitor (ruxolitinib). Similarly, the growth of primary human leukemia cells was inhibited in vitro and in mouse xenograft models when the cells were exposed to kinase inhibitors tailored to the genetic profile of the primary tumors.
There is a wealth of additional data in the article by Roberts et al. 5 that the leukemia community will be mining for some time. Mutations in transcription factors that are important for lymphoid development were found more frequently in patients with Ph-like ALL than in patients with non-Ph-like ALL. This observation, together with the pattern of concurrent mutations affecting cytokine receptor signaling, should inform the design of more accurate mouse models of this disease. In addition, the observation that the prognosis within the subgroup of patients with Ph-like ALL may be further refined by assessment of the status of the JAK2 or EPOR locus requires independent validation. Finally, therapeutic strategies need to be developed and tested for the minority of patients without kinase mutations, as well as for those with only Ras pathway mutations.
The study by Roberts et al. 5 represents a call to action in several respects. First, the role of tyrosine kinase inhibitors in the management of Ph-like ALL must be tested in prospective clinical trials. The improved outcome after the addition of tyrosine kinase inhibitors to cytotoxic chemotherapy for the treatment of Ph-positive ALL provides the basis for some optimism that a similar approach could be applied to Ph-like ALL. The study by Roberts et al. provides strong preclinical evidence that kinase-altering mutations are biologically relevant drivers in Ph-like ALL. Several anecdotal clinical responses described in their Supplementary Appendix (available at NEJM.org) are encouraging but will require systematic study in well-controlled clinical trials. Second, the frequency of Ph-like ALL among older adults is unknown, but the agedependent rise in the proportion of Ph-like cases in children and young adults raises the possibility that the poor prognosis for adults may be due in part to a higher prevalence of this disease phenotype. Clearly, the genetic features of ALL in adults require additional study, with the hope that this will reveal new therapeutic targets for these patients. Third, the potential prognostic and therapeutic significance of the Ph-like subtype mandates development of diagnostic tools that can be widely deployed. Geneexpression profiling remains a research technique that is not practical for routine use in diagnostic laboratories. Low-density gene-expression arrays or flow cytometry-based assays have been proposed as alternative diagnostic strategies, 6 but these methods require further refinement and validation. Finally, rapid-turnaround molecular profiling will be needed to identify potentially actionable mutations in patients with Ph-like ALL. Mutational profiling with the use of large gene panels is now widely available in academic centers and commercial laboratories, but many of these platforms do not include a strategy for gene-fusion detection.
Improvements in risk stratification and tailored treatment plans for children with precursor B-cell ALL represent major successes in pediatric oncology. The findings of Roberts et al. provide new opportunities for investigation in children and young adults with Ph-like ALL and may well be extended to address the unmet medical needs of older adults with precursor B-cell ALL.
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